Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | CASP3 | P42574 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29398074 | 0.89 | MDM4 (0.57) | MDM4TP53CASP3KMT2AMDM2 | |
| SCHEMBL29400538 | 0.89 | MDM4 (0.57) | MDM4TP53CASP3KMT2AMDM2 | |
| SCHEMBL29547329 | 0.89 | MDM4 (0.57) | MDM4TP53CASP3KMT2AMDM2 | |
| SCHEMBL30695566 | 0.89 | MDM4 (0.57) | MDM4TP53CASP3KMT2AMDM2 | |
| SCHEMBL12493153 | 0.89 | MDM4 (0.57) | MDM4TP53CASP3KMT2AMDM2 | |
| SCHEMBL29398455 | 0.89 | MDM4 (0.57) | MDM4TP53CASP3KMT2AMDM2 | |
| SCHEMBL29552281 | 0.89 | MDM4 (0.57) | MDM4TP53CASP3KMT2AMDM2 | |
| SCHEMBL119859 | 0.89 | MDM4 (0.57) | MDM4TP53CASP3KMT2AMDM2 | |
| SCHEMBL119866 | 0.89 | MDM4 (0.57) | MDM4TP53CASP3KMT2AMDM2 | |
| SCHEMBL29688201 | 0.89 | MDM4 (0.49) | MDM4TP53CASP3KMT2AEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080249106-A1 | 3-(1-((R)-7-((4-fluoropiperidin-1-yl)methyl)-3,4-dihydro-2H-chromen-4-yl)-1H-1,2,3-triazol-4-yl)-2-(4-methylphenylsulfonamido)propanoic acid; chronic pain analgesics; side effect reduction | AMGEN INC. | 2008-10-09 | — | — | US | disclosed |
| US-7414134-B2 | B1 bradykinin receptor antagonists | AMGEN INC. (US) | 2008-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249106-A1 | 3-(1-((R)-7-((4-fluoropiperidin-1-yl)methyl)-3,4-dihydro-2H-chromen-4-yl)-1H-1,2,3-triazol-4-yl)-2-(4-methylphenylsulfonamido)propanoic acid; chronic pain analgesics; side effect reduction | BDKRB1, BDKRB2, FPR1 | MDM4 4777/4885TP53 4446/4885CASP3 2103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.